NCT07378891 (FUNDUS AI) is a clinical trial in Diabetes (DM), sponsored by University Hospital Tuebingen.

Who is sponsoring NCT07378891?

NCT07378891 is sponsored by University Hospital Tuebingen.

What condition does NCT07378891 study?

NCT07378891 studies Diabetes (DM), Prediabetes.

Is NCT07378891 still recruiting?

NCT07378891 is currently enrolling by invitation. Last updated 10 February 2026.

Last reviewed 2026-02-10 · How we verify

NCT07378891: FUNDUS AI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI)

ENROLLING BY INVITATION Last updated 10 February 2026

What this trial tests

trial in Diabetes (DM) in 100 participants. Enrolling by invitation.

Timeline

1 December 2025

Primary endpoint
1 October 2028

15 December 2028

Quick facts

Lead sponsor	University Hospital Tuebingen
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 December 2025
Primary completion	1 October 2028
Estimated completion	15 December 2028
Sites	1 location across Germany

Conditions studied

Diabetes (DM) — all drugs for Diabetes (DM) →
Prediabetes — all drugs for Prediabetes →

Sponsor

University Hospital Tuebingen

Who can join

Adults 18 to 80, any sex, with Diabetes (DM) or Prediabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Examination of individuals with prediabetes and established diabetes for early signs of diabetic retinopathy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes (DM)

Currently open trials in the same condition.

NCT07530575 — Limosilactobacillus Fermentum CRL 1446 - CONICET CASASCO · NA · active not recruiting
NCT07167693 — Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes · Phase 1, PHASE2 · recruiting
NCT07205978 — Nut Consumption and Prevention of Non-communicable Diseases: A Global Individual Participant Data Meta-analysis · active not recruiting
NCT07252700 — Preventing Diabetes: Impact of an EMR-Based Intervention for Enhanced Pre-Diabetes Management in Primary Care · NA · recruiting
NCT07285330 — Dietitian-Nutritionist vs. Day Hospital in the Metabolic Control of Patients With Type 2 Diabetes · recruiting

Other University Hospital Tuebingen trials

Trials by the same sponsor.

NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
NCT07276503 — Verification of a New Predictive Delirium Score in Adults With Elective Cardiac Valve or Bypass Surgery With Perioperati · not yet recruiting
NCT07411365 — Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI · NA · not yet recruiting
NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07151378 — Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Comp · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07378891 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Tuebingen
Last refreshed: 10 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07378891.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing